KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit.

Transl Lung Cancer Res

Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.

Published: December 2019

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987348	PMC
http://dx.doi.org/10.21037/tlcr.2019.07.06	DOI Listing

Publication Analysis

keynote-042 rolls

rolls programmed

programmed cell

cell death

death ligand

ligand threshold

threshold non-small

non-small cell

cell lung

lung cancer

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!